Guests started to trickle in at 5:45 pm and within minutes the venue was jam packed and
Photo: Guests during networking at Boston QSP.
attendees were busy networking and enjoying the food. The talk part of the event started
Photo: Networking at Boston QSP.
promptly at 6:30 pm after a brief welcome by the co-organizer, Rajiv P. Shrestha.
Photo: Co-organizer Rajiv welcoming the guests and getting them seated.
The first speaker of the evening was Chandni Valiathan with her presentation titled “Translational model based dose selection in immuno-oncology.” The presentation was based on her work related to development of pembrolixumab (Keytruda) at Merck & Co. as an Associate Principal Scientist. She helped the audience to appreciate the complexities of a
Photo: Chandni during her talk.
model building process and the unconventional approach taken by Merck’s team. Initial clinical data was already available to guide early modeling and simulation (M&S) effort which enabled a more informed set of preclinical studies and so on to further improve the model. This led to informed changes in the decisions. Ultimately, the FDA approval for
Photo: Q&A after Chandni's presentation.
Keytruda was obtained for the dose recommended by the M&S team (2 mg/kg once every 3 weeks). Had the conventional approach been followed, the dose would perhaps have been 10 mg/kg once every 2 weeks. Chandni highlighted the limitations of existing preclinical models during Q&A which served as a perfect preamble for the second speaker, Christian Maass.
Christian is a Postdoc with the Translational Systems Pharmacology team led by Murat Cirit which is a part of MIT’s Physiomimetics program led by Linda G. Griffith. His talk was titled “Design and practical operation of single and multi-microphysiological devices for
Photo: Christian giving his talk.
systems pharmacology application.” In simple words, a microphysiological device (a chip) contains small fraction of actual human organ tissues and can mimic the organ.The idea is to use a network of such chips to develop a system that would mimic a more complicated interaction between different organs. The response of such a system to a new drug would mimic a test on humans. That could potentially be a game changer!
Post-talk Q&A sessions were lively and the networking sessions were cordial. Many attendees stuck around until it was time to clear up the venue.
Photo: Christian during the Q&A.
Thanks to the expert speakers and the enthusiastic attendees for making the first Boston QSP event a resounding success. The organizers are highly encouraged and look forward to presenting yet another successful event on November 14, 2016.
Please help us spread the word and grow this community!
Visit our Meetup and LinkedIn pages for updates and details.